Vertex’s Cystic Fibrosis Franchise Has Multiple Jump Points In 2015
This article was originally published in The Pink Sheet Daily
Executive Summary
Kalydeco revenues should build momentum this year, and Vertex’s franchise could see an even sharper uptick should its combination products reach the market.
You may also be interested in...
Vertex’s CF Therapy Combination Trial Yields Promising Lung-Function Data
Interim data from a Phase II study investigating Kalydeco with VX-809 showed statistically significant FEV-1 improvement across dosing groups; the company hopes to start a pivotal Phase III program for the combo in late 2012 or early 2013.
Vertex Gets Quick FDA Approval Of Kalydeco; Prices New CF Drug At $294,000 Per Year
Kalydeco, an oral CFTR potentiator, becomes the first approved drug to address the underlying cause of cystic fibrosis, rather than just treating the disease’s symptoms.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.